Piperlongumine (from Piper longum Root Extract)

COMMON NAME

Piperlongumine | Piplartine | Long pepper 

TOP BENEFITS OF PIPERLONGUMINE

Supports healthy aging *

Supports cellular health *

Supports healthy brain aging *

WHAT IS PIPERLONGUMINE?

Piperlongumine is an amide-alkaloid found in several species of pepper plants, most notably long pepper (Piper longum) from which it got its name. Long pepper is a close relative of one of the most widely used spices in the world, black pepper (Piper nigrum). The fruits and roots of long pepper are used as spices and in traditional healing systems including those found in India and Thailand. In Ayurveda, long pepper is considered a rasayana (rejuvenator), and black pepper and long pepper, along with ginger—collectively called Trikatu (“three pungent spices”)—is one of the most frequently used spice combinations. Long pepper has a taste similar to, but hotter and more complex than black pepper, and has often been used somewhat interchangeably as a spice: the word “pepper” is actually derived from the Sanskrit word for long pepper (pippali). Piperlongumine is one of the compounds that produce this stronger and more complex taste—long pepper fruits (and roots) contain piperlongumine, while black pepper does not. There has been a growing research interest in piperlongumine, with one of the areas of interest being as a potential senolytic compound.

NEUROHACKER’S PIPERLONGUMINE SOURCING

Piperlongumine is produced from the roots of Piper longum (long pepper). The high-purity standardized extract we use contains not less than 95% piperlongumine.

Piperlongumine is non-GMO, gluten-free, and vegan.

PIPERLONGUMINE FORMULATING PRINCIPLES AND RATIONALE

Research suggests that piperlongumine has a broad range of effective servings, depending on its intended use and other ingredients it’s combined with. We chose a 50 mg recommended serving for Qualia Senolytic because the data suggests that this amount may play a complementary role with other ingredients used in the formula, since piperlongumine may have a unique senolytic mechanism [1] and has been reported to complement another senolytic compound [2]. Piperlongumine has been studied in a wide range of amounts in animal research, with even very low amounts of piperlongumine—equivalent to about 2 mg daily for humans—supporting aspects of healthy function in mice when added to the diet consistently [3]. Much higher servings, equivalent to several hundred mg daily have also been used in research [4].* 

PIPERLONGUMINE KEY MECHANISMS

Supports brain function*

Supports hippocampal and cognitive function in aged mice* [5]

Supports neuroprotective functions* [3,6,7]

Supports neural mitochondrial function* [6]

Supports cerebral endothelial progenitor cell function* [3]

Influences neural immune signaling* [8,9]

Influences astrocyte and microglia activation* [9]

Supports healthy biobehavioral responses to stress* [10,11]

Promotes healthy aging and longevity*

Supports the management of senescent cells* [1,2]

Supports cellular functions involved with pruning stressed cells* [2,12–21]

Supports autophagy* [6,14–17,21–23]

Supports stress resistance* [4]

Influences immune signaling* [24]

Supports natural killer (NK) cell binding to stressed cells* [25]

Supports cellular signaling*

Influences PI3K/AKT signaling* [13–15,17,20]

Influences mTOR signaling* [13–15,17]

Influences NF-κB signaling* [8,13,26]

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

REFERENCES

[1]X. Zhang, S. Zhang, X. Liu, Y. Wang, J. Chang, X. Zhang, S.G. Mackintosh, A.J. Tackett, Y. He, D. Lv, R.-M. Laberge, J. Campisi, J. Wang, G. Zheng, D. Zhou, Aging Cell 17 (2018) e12780.

[2]Y. Wang, J. Chang, X. Liu, X. Zhang, S. Zhang, X. Zhang, D. Zhou, G. Zheng, Aging 8 (2016) 2915–2926.

[3]X.-H. Dong, C. Peng, Y.-Y. Zhang, Y. Jiang, L.-J. Yang, J.-B. He, X. Tao, C. Zhang, A.F. Chen, H.-H. Xie, Front. Pharmacol. 12 (2021) 689880.

[4]V. Yadav, S.S. Chatterjee, M. Majeed, V. Kumar, J Intercult Ethnopharmacol 4 (2015) 277–283.

[5]J. Go, T.-S. Park, G.-H. Han, H.-Y. Park, Y.-K. Ryu, Y.-H. Kim, J.H. Hwang, D.-H. Choi, J.-R. Noh, D.Y. Hwang, S. Kim, W.K. Oh, C.-H. Lee, K.-S. Kim, Int. J. Mol. Med. 42 (2018) 1875–1884.

[6]J. Liu, W. Liu, Y. Lu, H. Tian, C. Duan, L. Lu, G. Gao, X. Wu, X. Wang, H. Yang, Autophagy 14 (2018) 845–861.

[7]F. Ntagwabira, M. Trujillo, T. McElroy, T. Brown, P. Simmons, D. Sykes, A.R. Allen, Int. J. Mol. Sci. 23 (2022).

[8]N. Kim, J. Do, J.-S. Bae, H.K. Jin, J.-H. Kim, K.-S. Inn, M.S. Oh, J.K. Lee, J. Pharmacol. Sci. 137 (2018) 195–201.

[9]S.M. Gu, J. Yun, D.J. Son, H.Y. Kim, K.T. Nam, H.D. Kim, M.G. Choi, J.S. Choi, Y.M. Kim, S.-B. Han, J.T. Hong, Free Radic. Biol. Med. 103 (2017) 133–145.

[10]L. Zhang, C. Liu, M. Yuan, C. Huang, L. Chen, T. Su, Z. Liao, L. Gan, Behav. Pharmacol. 30 (2019) 722–729.

[11]V. Yadav, S.S. Chatterjee, M. Majeed, V. Kumar, Afr. J. Tradit. Complement. Altern. Med. 6 (2016) 413–423.

[12]D. Basak, S.R. Punganuru, K.S. Srivenugopal, Int. J. Oncol. 48 (2016) 1426–1436.

[13]S. Kumar, N. Agnihotri, Biomed. Pharmacother. 109 (2019) 1462–1477.

[14]H. Wang, Y. Wang, H. Gao, B. Wang, L. Dou, Y. Li, Oncol. Lett. 15 (2018) 1423–1428.

[15]F. Wang, Y. Mao, Q. You, D. Hua, D. Cai, Int. J. Immunopathol. Pharmacol. 28 (2015) 362–373.

[16]S.-Y. Chen, H.-Y. Huang, H.-P. Lin, C.-Y. Fang, Int. J. Mol. Med. (2019).

[17]P. Makhov, K. Golovine, E. Teper, A. Kutikov, R. Mehrazin, A. Corcoran, A. Tulin, R.G. Uzzo, V.M. Kolenko, Br. J. Cancer 110 (2014) 899–907.

[18]Q. Kang, S. Yan, Exp. Ther. Med. 9 (2015) 1345–1350.

[19]N. Allaman-Pillet, D.F. Schorderet, Oncotarget 12 (2021) 907–916.

[20]J. Zhou, Z. Huang, X. Ni, C. Lv, Toxicol. In Vitro 65 (2020) 104775.

[21]X.-X. Xiong, J.-M. Liu, X.-Y. Qiu, F. Pan, S.-B. Yu, X.-Q. Chen, Acta Pharmacol. Sin. 36 (2015) 362–374.

[22]Y. Wang, J.-W. Wang, X. Xiao, Y. Shan, B. Xue, G. Jiang, Q. He, J. Chen, H.-G. Xu, R.-X. Zhao, K.D. Werle, R. Cui, J. Liang, Y.-L. Li, Z.-X. Xu, Cell Death Dis. 4 (2013) e824.

[23]W. Ye, T. Tang, Z. Li, X. Li, Q. Huang, J. Cardiol. 79 (2022) 134–143.

[24]J. Shi, Y. Xia, H. Wang, Z. Yi, R. Zhang, X. Zhang, Front. Pharmacol. 12 (2021) 818326.

[25]L.O. Afolabi, J. Bi, L. Chen, X. Wan, Int. Immunopharmacol. 96 (2021) 107658.

[26]S. Kumar, N. Agnihotri, Mol. Cell. Biochem. 476 (2021) 1765–1781.